<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770207</url>
  </required_header>
  <id_info>
    <org_study_id>DEB on malignant tumors</org_study_id>
    <nct_id>NCT04770207</nct_id>
  </id_info>
  <brief_title>Intra-tumor Injection of Drug-eluting Microspheres</brief_title>
  <official_title>Intra-tumor Injection of Drug-eluting Microspheres for Treatment of Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and clinical effect of injection of drug-eluting microspheres into&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessing side effects and treatment efficacy after injection of drug-eluting microspheres&#xD;
      into malignant tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Assessing incidence of side effects and primary clinical response of the intra-tumor injection of DEB in advanced solid cancers, including CR, PR, SD, and PD.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Tumor diameter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of tumor diameter one month after injection of drug-eluting microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of drug-eluting microspheres into malignant tumors</intervention_name>
    <description>Under the guidance of CT, puncture needle was used to inject drug-eluting microspheres into the tumor</description>
    <arm_group_label>Tumor diameter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Solid advanced malignant tumors&#xD;
&#xD;
          -  Age between18 and 99 years&#xD;
&#xD;
          -  Life expectancy is greater than three months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Benign tumor&#xD;
&#xD;
          -  Life expectancy is less than three months&#xD;
&#xD;
          -  Serious medical comorbidity&#xD;
&#xD;
          -  Others&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenfeng Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bingjia He, MD</last_name>
    <phone>+862039195965</phone>
    <email>464677938@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenfeng Zhang, MD, PhD</last_name>
    <phone>+862039195966</phone>
    <email>zhangzhf@gzhmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BINGJIA HE, MD</last_name>
      <phone>13560199303</phone>
      <email>464677938@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhenfeng Zhang, MD, PhD</last_name>
      <phone>+862039195966</phone>
      <email>zhangzhf@gzhmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Borde T, Laage Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, Rexha I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Gebauer B, Hyder F, Coman D, van Breugel JMM, Chapiro J. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. J Vasc Interv Radiol. 2020 Oct;31(10):1706-1716.e1. doi: 10.1016/j.jvir.2020.04.010. Epub 2020 Jul 17.</citation>
    <PMID>32684417</PMID>
  </reference>
  <reference>
    <citation>Binder S, Lewis AL, LÃ¶hr JM, Keese M. Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. World J Gastroenterol. 2013 Nov 21;19(43):7586-93. doi: 10.3748/wjg.v19.i43.7586. Review.</citation>
    <PMID>24282349</PMID>
  </reference>
  <reference>
    <citation>Baur J, Ritter CO, Germer CT, Klein I, Kickuth R, Steger U. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med. 2016 Jun 20;8:69-74. doi: 10.2147/HMER.S105395. eCollection 2016.</citation>
    <PMID>27382341</PMID>
  </reference>
  <reference>
    <citation>Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008 Oct;8(10):1643-50. doi: 10.1586/14737140.8.10.1643. Review.</citation>
    <PMID>18925855</PMID>
  </reference>
  <reference>
    <citation>Rossi SM, Murray T, McDonough L, Kelly H. Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. Expert Opin Drug Deliv. 2021 May;18(5):607-623. doi: 10.1080/17425247.2021.1856074. Epub 2020 Dec 16.</citation>
    <PMID>33253052</PMID>
  </reference>
  <reference>
    <citation>Fuchs K, Duran R, Denys A, Bize PE, Borchard G, Jordan O. Drug-eluting embolic microspheres for local drug delivery - State of the art. J Control Release. 2017 Sep 28;262:127-138. doi: 10.1016/j.jconrel.2017.07.016. Epub 2017 Jul 11. Review.</citation>
    <PMID>28710006</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma; Lung Cancer</keyword>
  <keyword>Drug-eluting Beads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

